公共文化服务平台

共 1 条记录，以下是 1-9

全选清除导出

排序方式：

SITE-SPECIFIC HYPOMETHYLATION WITHIN PROMOTER CPG ISLAND OF PON1 WAS ASSOCIATED WITH BLEEDING EVENTS IN DUAL ANTIPLATELET-TREATED HAN CHINESE PATIENTS AFTER PCI: To evaluate the role of the DNA methylation of the CpG island within the PON1 promoter on the clinical efficac...; 钟诗龙康彦红陈纪言李新新张莹劳海燕余细勇

Plasma miR-126 as a potential marker predicting major adverse cardiac events in dual antiplatelet-treated patients after percutaneous coronary intervention: Aims:Antiplatelet treatment could cause a change in plasma levels of platelet microRNAs(miRNAs).However,it is ...; 余细勇Ji-Yan ChenZhi-Wei ZhengHong WuLi-Wen LiZhi-Wei ZhangZhi-Hong ChenQiu-Xiong LinYa-Ling Han钟诗龙; 文献传递

PON1基因启动子多态性及非遗传因素对PCI术后抗血小板治疗临床效应的影响被引量：6: 2012年; 目的对氧磷脂酶1(PON1)启动子CpG岛区基因多态性可能会影响氯吡格雷的抗血小板疗效。本研究探讨PON1基因启动子区多态性位点-108C/T,-126 G/C和-162G/A以及高血压、糖尿病等非遗传因素对行经皮冠状动脉介入治疗(PCI术)的冠心病患者氯吡格雷抗血小板临床效应的影响。方法根据纳入和排除标准,入选在广东省人民医院行PCI术患者538名,收集患者的临床资料,采用PCR直接测序的方法检测基因型,使用SAS9.1和HPlus软件分析其与氯吡格雷抗血小板效应的关系。结果 PON1启动子区-108C/T,-126 G/C和-162G/A位点,基因型为野生型或突变性对氯吡格雷抗血小板效应差异均无显著性(P>0.05);患者合并高血压[HR(95%CI)=3.837]、糖尿病(HR=2.715)或使用钙离子拮抗剂(HR=2.686)时,PCI术后出现MACE的风险较高(P<0.05)。结论 PON1基因启动子CpG岛区-108C/T,-126 G/C和-162G/A基因变异对接受氯吡格雷抗血小板治疗的冠心病患者在PCI术后出现主要不良心脏事件(MACE)无明显影响。患者合并高血压、糖尿病或使用钙离子拮抗剂会增加PCI术后出现MACE的风险。; 康彦红劳海燕陈秀云麦丽萍余细勇陈纪言钟诗龙; 关键词：对氧磷脂酶1 抗血小板治疗主要不良心脏事件非遗传因素

Site-specific hypomethylation within promoter CpG island of PON1 was associated with bleeding events in dual antiplatelet-troatod Han Chinese patients after PCI: ＜正＞Aim:To evaluate the role of the DNA methylation of the CpG island within the PON1 promoter on the clinical ...; Shi-long ZHONGYan-hong KANGJi-yan CHENXin-xin LIYing ZHANGHai-yan LAOXi-yong YU; 关键词：CLOPIDOGREL; 文献传递

Plasma miR-126 as a potential marker predicting major adverse cardiac events in patients after percutaneous coronary intervention: AIM:Circulating miRNAs have been considered as promising novel biomarkers for prognosis of cardiovascular dise...; ZHENG Zhi-weiYU Xi-yongCHEN Ji-yanWU HongLI Li-wenCHEN Zhi-hongHAN Ya-LingZHONG Shi-Long

Plasma miR-197 and miR-486-3p as potential novel diagnostic biomarkers for hypertension: AIM:Circulating microRNAs(miRNAs) have attracted much attention as promising novel markers for various disease...; LI Xin-xinLIU Xiao-qingFENG Ying-qingYU Xi-yongMAI Li-pingZHENG Wei-zhiZHONG Shi-long

PON1基因启动子多态性及非遗传因素对PCI术后抗血小板治疗临床效应的影响: 目的:对氧磷脂酶1(PON1)启动子CpG岛区基因多态性可能会影响氯吡格雷的抗血小板疗效。本研究探讨PON1基因启动子区多态性位点-108C/T、-126 G/C和-162G/A以及高血压、糖尿病等非遗传因素对行经皮冠状...; 康彦红劳海燕陈秀云麦丽萍余细勇陈纪言钟诗龙

SITE-SPECIFIC HYPOMETHYLATION WITHIN PROMOTER CPG ISLAND OF PON1 WAS ASSOCIATED WITH BLEEDING EVENTS IN DUAL ANTIPLATELET-TREATED HAN CHINESE PATIENTS AFTER PCI: ＜正＞To evaluate the role of the DNA methylation of the CpG island within the PON1 promoter on the clinical effi...; 钟诗龙康彦红陈纪言李新新张莹劳海燕余细勇

CYP2C19 and PON1 genetic variants as potential predictors for the risk of bleeding in antiplatelet-treated patients: AIM:Bleeding has emerged as an important outcome in antiplatelet treatment after percutaneous coronary interve...; ZHONG Shi-longYU Xi-yongWU HongZHANG BinKANG Yan-hongZHENG Zhi-weiWANG LingLIN Qiu-xiongSHAN Zhi-xinCHEN Ji-yan

全选清除导出

共1页<1>

广东省自然科学基金(S2011010005830)